The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism
Information source: University Hospital Inselspital, Berne
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypopituitarism; Hydrocortisone; Lipids; Fatty Acids, Nonesterified; Insulin Sensitivity
Intervention: Hydrocortisone (Drug); Placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University Hospital Inselspital, Berne Official(s) and/or principal investigator(s): Emanuel Christ, MD, PhD, Principal Investigator, Affiliation: Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern Chris Boesch, MD, PhD, Principal Investigator, Affiliation: AMSM; Division of Radiology, University Hopsital of Bern, Inselspital
Overall contact: Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch
Summary
This study aims at assessing the effect of today's standard of hydrocortisone dosage versus
previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL
and IHCL) after a standardised fat load followed by a short-term aerobic exercise in
patients with corticotropic pituitary insufficiency.
Clinical Details
Official title: The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids (Intrahepatocellular IHCL and Intramyocellular IMCL) in Patients With Corticotropic Hypopituitarism, a Randomised Placebo-controlled Double-blind Trial
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Change from baseline in flexibility of Intramyocellular Lipids (IMCL) Measured in mmol/LChange from baseline in flexibility of Intrahepatocellular Lipids (IHCL) Measured in mmol/L
Secondary outcome: Free Fatty Acids (FFA) availability during exercise before and after additional hydrocortisone/placebo Measured in mmol/LFlexibility of ectopic fat stores, defined as difference between intramyocellular/intrahepatocellular lipid concentration before and after exercise, and their possible relation to insulin sensitivity before and after additional hydrocortisone/placebo Free Fatty Acids (FFA) availability during exercise and the possible relation to insulin sensitivity before and after additional hydrocortisone/placebo Measured in mmol/L Effect of exercise on insulin at baseline Effect of exercise on insulin at 3 months Effect of exercise on catecholamines at baseline Effect of exercise on catecholamines at 3 months Effect of exercise on growth hormone at baseline Effect of exercise on growth hormone at 3 months Effect of exercise on cortisol at baseline Effect of exercise on cortisol at 3 months Effect of exercise on lactate at baseline Effect of exercise on lactate at 3 months Effect of exercise on glucose at baseline Effect of exercise on glucose at 3 months Effect of exercise on inflammatory markers at baseline Effect of exercise on inflammatory markers at 3 months
Detailed description:
Background
The investigators and others have shown that long-term hydrocortisone replacement therapy at
higher doses of hydrocortisone replacement therapy at higher doses of hydrocortisone
replacement (as previously recommended) is associated with higher mortality. The
pathophysiology for the association of hydrocortisone-replacement dose and mortality remains
unclear. A possible underlying mechanism is nonalcoholic fatty liver disease which is more
prevalent in patients with hypopituitarism. Patients with non-alcoholic fatty liver disease
are at a higher risk for overall-mortality.
It remains to be established whether the insulin resistance, associated with increased
intrahepatocellular lipids and increased intramusculoskeletal lipids, is implicated in the
pathophysiology of these epidemiological findings.
Interestingly, it has been shown that a reduction of hydrocortisone replacement dose from
20-30mg/d to 10-15mg/d resulted in a loss of body fat and a significant decrease of plasma
total cholesterol and triglyceride concentration. The effect of IMCL and IHCL is so far
unknown.
Patients with hypopituitarism with hydrocortisone replacement therapy provide a unique
disease model to study the short-term effects of previously recommended dose (higher dose)
of hydrocortisone versus lower dose of HC replacement therapy on ectopic lipids (IMCL; IHCL)
lipids, as well as on subcutaneous and visceral fat mass and on parameters of insulin
resistance. Combining MRI and MR-spectroscopy techniques, different fat mass (subcutaneous
and visceral) and ectopic lipids can be repeatedly and non-invasively assessed.
Objective
To investigate the impact of today's standard of hydrocortisone dosage (lower) versus
previous (higher) hydrocortisone dosage on flexibility and partitioning of ectopic lipid
depots after a standardised fat load followed by a short-term aerobic exercise in patients
with corticotropic pituitary insufficiency.
Methods
Ectopic lipids are measured by MR-spectroscopy, separate assessment of visceral and
subcutaneous fat mass will be performed by MR-imaging, standardized exercise capacity test
using spiroergometry. Short-time exercise consists of 2h aerobic cycling at 50% VO2max.
Laboratory analysis include lipid profile, free fatty acids, HOMA-Index, hormones.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Written informed consent
- Male and female patients
- Corticotropic pituitary insufficiency
- Capable to exercise during 120 minutes on a bicycle
- Normal ECG during ergometry
Exclusion Criteria
- Concomitant medication with NSAID, anticoagulants, digoxin, salbutamol,
anticonvulsants, cholinesterase inhibitor, pancuronium
- Abnormal liver, renal or thyroid function, heart failure
- Hemophilia
- Diabetes mellitus
- Severe dyslipidemia
- Active neoplasia
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Lack of safe contraception
- Known or suspected non-compliance
- Drug or alcohol abuse
- Inability to follow the procedures of the study
- Participation in another study with investigational drug within the 30 days preceding
and during the study
- Previous enrolment into current study
- Enrolment of the investigator, his/her family members, employees and other dependent
persons
- Inability to exercise
- Contraindications to exposure to a 3 T magnetic field
- Major depression, psychosis, claustrophobia
Locations and Contacts
Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch
Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Berne, Berne 3010, Switzerland; Recruiting Emanuel Christ, MD, PhD, Phone: +41 31 632 40 74, Email: emanuel.christ@insel.ch Emanuel Christ, MD, PhD, Principal Investigator
Additional Information
Related publications: Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 1997 Apr;37(4):484-93. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary. 2008;11(3):279-85. doi: 10.1007/s11102-008-0126-2.
Starting date: January 2015
Last updated: August 19, 2015
|